Electrical Nerve Stimulation associated exercises in patients with low back pai
- Conditions
- ow Back PainC23.888.592.612.274
- Registration Number
- RBR-86bzhkv
- Lead Sponsor
- niversidade Federal do Rio Grande do Norte
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Men and women; between 18 and 60 years of age; body mass index between 18.5 and 30 kg/m2; non-specific low back pain for at least 12 weeks and pain at least 3 on Visual Analog Scale - VAS; without prior contact with any electrotherapy current; absence of red flags such as - fracture, infection, tumor, inflammatory arthritis, pain with radicular characteristics, spondylolisthesis and spinal canal stenosis; without previous surgeries in the lumbar spine; no chronic use of analgesic opioids; no skin changes or changes in sensitivity at the application site; without pregnancy and pacemaker use
Participants who start using analgesics that modulate the primary outcome during treatment; accidents that prevent the exercise protocol; pregnanc; death and change of residence from the study state
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in Pain, assessed using the sit-to-stand test (how much pain it felt when performing the movement) and the pressure algometer. Data collected before, after each session, after the protocol and 1 month after the end of the protocol.
- Secondary Outcome Measures
Name Time Method Decrease in Kinesiophobia, assessed by the TAMPA scale. Data will be evaluated before, after the end of treatment and 1 month after the end of treatment.;Global perception of treatment will be assessed at the end of treatment.;Adherence will be evaluated at the end of treatment.;Improvement in Functional Capacity, assessed by the Roland-Morris questionnaire and functional sit-to-stand test. Data will be evaluated before, after the end of treatment and 1 month after the end of treatment.;Improved quality of life, assessed using the SF-36 questionnaire. Data will be evaluated before, after the end of treatment and 1 month after the end of treatment.;Decreased Fear, as assessed by the Fear Avoidance Beliefs Questionnaire. Data will be evaluated before, after the end of treatment and 1 month after the end of treatment.